Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Correction to A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.

Fouqué A, Delalande O, Jean M, Castellano R, Josselin E, Malleter M, Shoji KF, Hung MD, Rampanarivo H, Collette Y, van de Weghe P, Legembre P.

J Med Chem. 2019 Oct 24;62(20):9339-9340. doi: 10.1021/acs.jmedchem.9b01578. Epub 2019 Oct 11. No abstract available.

PMID:
31603322
2.

A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells.

Arfaoui A, Rioualen C, Azzoni V, Pinna G, Finetti P, Wicinski J, Josselin E, Macario M, Castellano R, Léonard-Stumpf C, Bal A, Gros A, Lossy S, Kharrat M, Collette Y, Bertucci F, Birnbaum D, Douik H, Bidaut G, Charafe-Jauffret E, Ginestier C.

EMBO Mol Med. 2019 Oct;11(10):e9930. doi: 10.15252/emmm.201809930. Epub 2019 Sep 2.

3.

A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer.

Del Bano J, Florès-Florès R, Josselin E, Goubard A, Ganier L, Castellano R, Chames P, Baty D, Kerfelec B.

Front Immunol. 2019 Jul 10;10:1593. doi: 10.3389/fimmu.2019.01593. eCollection 2019.

4.

Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer.

Karkeni E, Morin SO, Bou Tayeh B, Goubard A, Josselin E, Castellano R, Fauriat C, Guittard G, Olive D, Nunès JA.

Front Immunol. 2019 Jun 6;10:1307. doi: 10.3389/fimmu.2019.01307. eCollection 2019.

5.

The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/β-Catenin Signaling.

Lopez Almeida L, Sebbagh M, Bertucci F, Finetti P, Wicinski J, Marchetto S, Castellano R, Josselin E, Charafe-Jauffret E, Ginestier C, Borg JP, Santoni MJ.

Stem Cell Reports. 2018 Nov 13;11(5):1040-1050. doi: 10.1016/j.stemcr.2018.09.008. Epub 2018 Oct 18.

6.

Establishment of a mouse xenograft model of metastatic adrenocortical carcinoma.

Morin A, Ruggiero C, Robidel E, Doghman-Bouguerra M, Das AT, Castellano R, Josselin E, Favier J, Lalli E.

Oncotarget. 2017 Apr 7;8(31):51050-51057. doi: 10.18632/oncotarget.16909. eCollection 2017 Aug 1.

7.

Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.

M-Rabet M, Cabaud O, Josselin E, Finetti P, Castellano R, Farina A, Agavnian-Couquiaud E, Saviane G, Collette Y, Viens P, Gonçalves A, Ginestier C, Charafe-Jauffret E, Birnbaum D, Olive D, Bertucci F, Lopez M.

Ann Oncol. 2017 Apr 1;28(4):769-776. doi: 10.1093/annonc/mdw678.

8.

PRICKLE1 Contributes to Cancer Cell Dissemination through Its Interaction with mTORC2.

Daulat AM, Bertucci F, Audebert S, Sergé A, Finetti P, Josselin E, Castellano R, Birnbaum D, Angers S, Borg JP.

Dev Cell. 2016 May 23;37(4):311-325. doi: 10.1016/j.devcel.2016.04.011. Epub 2016 May 12.

9.

A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.

Fouqué A, Delalande O, Jean M, Castellano R, Josselin E, Malleter M, Shoji KF, Hung MD, Rampanarivo H, Collette Y, van de Weghe P, Legembre P.

J Med Chem. 2015 Aug 27;58(16):6559-73. doi: 10.1021/acs.jmedchem.5b00991. Epub 2015 Aug 14. Erratum in: J Med Chem. 2019 Oct 24;62(20):9339-9340.

PMID:
26237138
10.

Nectin-4 mutations causing ectodermal dysplasia with syndactyly perturb the rac1 pathway and the kinetics of adherens junction formation.

Fortugno P, Josselin E, Tsiakas K, Agolini E, Cestra G, Teson M, Santer R, Castiglia D, Novelli G, Dallapiccola B, Kurth I, Lopez M, Zambruno G, Brancati F.

J Invest Dermatol. 2014 Aug;134(8):2146-2153. doi: 10.1038/jid.2014.119. Epub 2014 Feb 27.

11.

ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program.

Charafe-Jauffret E, Ginestier C, Bertucci F, Cabaud O, Wicinski J, Finetti P, Josselin E, Adelaide J, Nguyen TT, Monville F, Jacquemier J, Thomassin-Piana J, Pinna G, Jalaguier A, Lambaudie E, Houvenaeghel G, Xerri L, Harel-Bellan A, Chaffanet M, Viens P, Birnbaum D.

Cancer Res. 2013 Dec 15;73(24):7290-300. doi: 10.1158/0008-5472.CAN-12-4704. Epub 2013 Oct 18.

12.

The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.

Salvador MA, Wicinski J, Cabaud O, Toiron Y, Finetti P, Josselin E, Lelièvre H, Kraus-Berthier L, Depil S, Bertucci F, Collette Y, Birnbaum D, Charafe-Jauffret E, Ginestier C.

Clin Cancer Res. 2013 Dec 1;19(23):6520-31. doi: 10.1158/1078-0432.CCR-13-0877. Epub 2013 Oct 18.

13.

Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer.

Mezil L, Berruyer-Pouyet C, Cabaud O, Josselin E, Combes S, Brunel JM, Viens P, Collette Y, Birnbaum D, Lopez M.

PLoS One. 2012;7(9):e43409. doi: 10.1371/journal.pone.0043409. Epub 2012 Sep 18.

14.

Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target.

Ginestier C, Monville F, Wicinski J, Cabaud O, Cervera N, Josselin E, Finetti P, Guille A, Larderet G, Viens P, Sebti S, Bertucci F, Birnbaum D, Charafe-Jauffret E.

Stem Cells. 2012 Jul;30(7):1327-37. doi: 10.1002/stem.1122.

15.

Effects of deletion of macrophage ABCA7 on lipid metabolism and the development of atherosclerosis in the presence and absence of ABCA1.

Meurs I, Calpe-Berdiel L, Habets KL, Zhao Y, Korporaal SJ, Mommaas AM, Josselin E, Hildebrand RB, Ye D, Out R, Kuiper J, Van Berkel TJ, Chimini G, Van Eck M.

PLoS One. 2012;7(3):e30984. doi: 10.1371/journal.pone.0030984. Epub 2012 Mar 5. Erratum in: PLoS One. 2012;7(5). doi:10.1371/annotation/577d9009-baf4-46ea-b44e-eda094b604db.

16.

Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth.

Fournier G, Cabaud O, Josselin E, Chaix A, Adélaïde J, Isnardon D, Restouin A, Castellano R, Dubreuil P, Chaffanet M, Birnbaum D, Lopez M.

Oncogene. 2011 Sep 8;30(36):3862-74. doi: 10.1038/onc.2011.106. Epub 2011 Apr 11.

PMID:
21478912
17.

Mutations in PVRL4, encoding cell adhesion molecule nectin-4, cause ectodermal dysplasia-syndactyly syndrome.

Brancati F, Fortugno P, Bottillo I, Lopez M, Josselin E, Boudghene-Stambouli O, Agolini E, Bernardini L, Bellacchio E, Iannicelli M, Rossi A, Dib-Lachachi A, Stuppia L, Palka G, Mundlos S, Stricker S, Kornak U, Zambruno G, Dallapiccola B.

Am J Hum Genet. 2010 Aug 13;87(2):265-73. doi: 10.1016/j.ajhg.2010.07.003.

18.

Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP.

Frigui W, Bottai D, Majlessi L, Monot M, Josselin E, Brodin P, Garnier T, Gicquel B, Martin C, Leclerc C, Cole ST, Brosch R.

PLoS Pathog. 2008 Feb 8;4(2):e33. doi: 10.1371/journal.ppat.0040033.

Supplemental Content

Loading ...
Support Center